Nureca P/E Ratio
Nureca P/E ratio. Nureca (NURECA) P/E ratio is not applicable — EPS (TTM) ₹2.11, 1 consecutive loss quarter. See Healthcare peers with valid P/E ratios below.
P/E Ratio Status
N/A
Loss Making
Company is currently reporting losses
P/E Ratio Not Applicable
Company reported a loss in the most recent quarter. P/E ratio is not meaningful for loss-making periods.
Consecutive Loss Quarters: 1
Current EPS: ₹2.11
Recent Quarterly Performance
| Quarter | EPS (₹) | Net Profit (₹ Cr) | Status |
|---|---|---|---|
| Mar 2026 | -6.45 | -6 | Loss |
| Jun 2026 | 3.21 | 3 | Profit |
| Sept 2025 | 3.63 | 4 | Profit |
| Mar 2025 | 2.47 | 3 | Profit |
| Jun 2025 | 0.81 | 1 | Profit |
| Dec 2025 | 3.91 | 4 | Profit |
| Sept 2024 | -0.48 | -1 | Loss |
| Mar 2024 | -4.15 | -4 | Loss |
Healthcare Peers with Valid P/E Ratios — NURECA Comparison
Healthcare sector average P/E 54.67, median 31.4 — NURECA excluded (negative EPS).
Sector Average PE
54.67
Sector Median PE
31.4
Lowest PE
2.02
Profitable Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.02 | ₹60 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.33 | ₹55 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.86 | ₹6,006 | Low |
| Dipna Pharmachem | DPL | 3.97 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 5.05 | ₹65 | Low |
| Royal Sense | ROYAL | 5.39 | ₹40 | Low |
| Kabra Drugs | KABRADG | 5.47 | ₹41 | Low |
| GKB Ophthalmics | GKB | 5.85 | ₹32 | Low |
| Colinz Laboratories | COLINZ | 6.31 | ₹18 | Low |
Related Analysis
- For live price, revenue and the complete fundamental profile, see Nureca share price chart.
- Examine Nureca quarterly earnings for recent quarterly revenue, profit and EPS trends.
- Also explore NURECA price trends to track price trends across different timeframes.